177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study)

Kambiz Rahbar; Markus Essler; Matthias Eiber; Christian la Fougère; Vikas Prasad; Wolfgang P. Fendler; Philipp Rassek; Ergela Hasa; Helmut Dittmann; Ralph A. Bundschuh; Kim M. Pabst; Milena Kurtinecz; Anja Schmall; Frank Verholen; Oliver Sartor

doi:10.2967/jnumed.123.266125

Research ArticleClinical Investigation

Open Access

¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior ²²³Ra (RALU Study)

Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Wolfgang P. Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Kim M. Pabst, Milena Kurtinecz, Anja Schmall, Frank Verholen and Oliver Sartor

Journal of Nuclear Medicine December 2023, 64 (12) 1925-1931; DOI: https://doi.org/10.2967/jnumed.123.266125

Kambiz Rahbar

1Department of Nuclear Medicine, University of Münster Medical Center, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Markus Essler

2Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthias Eiber

3Department of Nuclear Medicine, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christian la Fougère

4Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vikas Prasad

5Department of Nuclear Medicine, University of Ulm, Ulm, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang P. Fendler

6Department of Nuclear Medicine, German Cancer Consortium University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Philipp Rassek

1Department of Nuclear Medicine, University of Münster Medical Center, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ergela Hasa

3Department of Nuclear Medicine, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Helmut Dittmann

4Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ralph A. Bundschuh

2Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kim M. Pabst

6Department of Nuclear Medicine, German Cancer Consortium University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Milena Kurtinecz

7Bayer HealthCare Pharmaceuticals, Whippany, New Jersey;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anja Schmall

8Bayer Consumer Care, Basel, Switzerland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frank Verholen

8Bayer Consumer Care, Basel, Switzerland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Oliver Sartor

9Tulane Cancer Center, Tulane Medical School, New Orleans, Louisiana

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 64, Issue 12

December 1, 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study)

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior ²²³Ra (RALU Study)

Journal of Nuclear Medicine Dec 2023, 64 (12) 1925-1931; DOI: 10.2967/jnumed.123.266125

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior ²²³Ra (RALU Study)

Journal of Nuclear Medicine Dec 2023, 64 (12) 1925-1931; DOI: 10.2967/jnumed.123.266125

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Erratum

PubMed
Google Scholar

Cited By...

Sequential and Combination Therapies of 223RaCl2 and Prostate-Specific Membrane Antigen Radioligand Therapy

Google Scholar

Keywords

targeted α-therapy
223Ra
177Lu-PSMA
metastatic castration-resistant prostate cancer
real-world practice

Main menu

User menu

Search

¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior ²²³Ra (RALU Study)

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords